• Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Bloggers
    Bloggers Search for your favorite blogger from this site.
  • Archives
    Archives Contains a list of blog posts that were created previously.
  • Login
    Login Login form
11

Please save the date for our

First Quarterly MISTIE III Safety Forum

 

To be held via webinar

Wednesday, June 10th, 1-2pm EDT

 

Agenda

·       Equipoise in MISTIE III - Andrew Carlson, MD, University of New Mexico

·       Quarter-Mile Marker: Where Do We Stand Surgically? - Surgical Center Leadership

·       Heparin Use in MISTIE III – Safety Committee

 

Please RSVP to your Site Manager and register here: https://attendee.gotowebinar.com/register/5377708438901189377

 

 

 

Once registered, webinar details will be e-mailed to you.  All are welcome to attend.

225

The 500th and final patient in the CLEAR-III trial was randomized on 14-Jan-2015, closing the enrollment period for this trial. Sites have until the end of January to enter any remaining screens. The trial continues in follow-up with the last patient's last visit (LPLV) expected in February 2016. 

405

Good news everyone! Inservice training slides are now available in the documents section under Training Files. These are specifically designed to give non-core team members at your site a quick but comprehensive overview of the trial. 

http://braininjuryoutcomes.com/mistie-documents/viewcategory/66 

587


The new MISTIE-III mobile application is now finished! It is currently available for download on the iPhone and Android devices and can also be accessed using this link: http://braininjuryoutcomes.com/mistie-mobile/web/mistie.php

 

    b2ap3_thumbnail_Screen-Shot-2014-12-02-at-12.08.59-PM.png                 b2ap3_thumbnail_SamJPEG.png

 

The MISTIE-III MOBILE APP has the following features:

  • A link to the VISION EDC
  • Important Phone Numbers
  • Surgical Review Checklist
  • Inclusion/Exclusion Criteria
  • Schedule of Evaluations
  • Protocol at a Glance
  • ABC/2 Calculator
  • Dosing Guidance
  • NIH Stroke Scale Calculator
  • Modified Rankin Assessment
  • Stability Decision-making
  • Prohibited Medications
  • Catheter Tract Algorithm

                                                 b2ap3_thumbnail_Screen-Shot-2014-12-02-at-12.09.28-PM.png

 

578

Dr. David Newman-Toker and the Brain Injury Outcomes (BIOS) coordinating center at Johns Hopkins University are happy to announce that The National Institute on Deafness and Other Communication Disorders (NIDCD), one of the National Institutes of Health (NIH), has awarded funding for the AVERT clinical trial (FAIN U01DC013778). AVERT (Acute Video-oculography for vertigo in Emergency rooms for Rapid Triage) is a randomized controlled trial evaluating the algorithmic application of a diagnostic medical device (video-oculography or VOG)  in the triage of patients presenting to hospital emergency departments with vertigo and dizziness.

The study is expected to randomize 226 patients across 3 U.S.-based clinical sites. The study has been deemed a non-significant risk device trial by the U.S. FDA as it involves a new (investigational) application of this device. VOG devices are currently FDA-approved for measuring eye movements in the assessment of vestibular conditions; they have not been used extensively in the emergency department setting prior to this trial. The study is currently under review by the Institutional Review Boards at the participating sites and is expected to start enrolling next year.

Continue reading